WVP
CLRB icon

Worth Venture Partners’s Cellectar Biosciences CLRB Stock Holding History

Worth Venture Partners’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,130
Closed -$1.92M – 82
2023
Q4 		$1.92M Buy
23,130
+13,826
+149% +$1.03M 1.04% 34
2023
Q3 		$737K Sell
9,304
-1,146
-11% -$67.5K 0.44% 62
2023
Q2 		$611K Sell
10,450
-770
-7% -$37K 0.33% 67
2023
Q1 		$485K Hold
11,220
– – 0.24% 86
2022
Q4 		$576K Buy
11,220
+9,832
+708% +$589K 0.34% 71
2022
Q3 		$140K Sell
1,388
-139
-9% -$20K 0.09% 126
2022
Q2 		$225K Hold
1,527
– – 0.13% 110
2022
Q1 		$315K Buy
1,527
+841
+123% +$147K 0.15% 98
2021
Q4 		$137K Buy
+686
New +$165K 0.07% 109
2020
Q4 		– Sell
-585
Closed -$218K – 105
2020
Q3 		$218K Sell
585
-745
-56% -$294K 0.18% 88
2020
Q2 		$511K Buy
+1,330
New +$558K 0.25% 64

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Worth Venture Partners's CLRB Position: Q1 2024 in Review

Worth Venture Partners sold out of Cellectar Biosciences (CLRB) in Q1 2024, closing a stake of 23,130 shares — an estimated $1.92M sold.

Worth Venture Partners first reported a position in CLRB in Q2 2020 and held it in 11 quarters. The position peaked at $1.92M in Q4 2023. 45 funds tracked by Wall St. Rank hold CLRB as of Q1 2024.

  • Worth Venture Partners reported no remaining Cellectar Biosciences position as of Q1 2024 after selling out during the quarter.
  • Worth Venture Partners sold 23,130 Cellectar Biosciences shares in Q1 2024, an estimated $1.92M.
  • Worth Venture Partners first reported a position in Cellectar Biosciences in Q2 2020 and held it in 11 quarters.
  • Worth Venture Partners's Cellectar Biosciences position peaked at $1.92M in Q4 2023.
  • 45 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.